Skip to content

PEDIATRIX MEDICAL GROUP INC (MD)

Health Care · Healthcare Services - Physician Groups · NYSE

Pediatrix Medical Group is a leading provider of specialized maternal-fetal and pediatric physician services in the United States.

What PEDIATRIX MEDICAL GROUP INC does

Pediatrix Medical Group is a national medical group that provides physician and other clinical services in neonatal, maternal-fetal, pediatric, and other pediatric subspecialties. The company operates through a network of affiliated physician practices, delivering integrated care to infants, children, and their families across various clinical settings.

Themes: healthcare services, neonatal care, pediatric subspecialties, clinical services

Fundamentals

  • Price$26.57 as of 2026-08-21 close
  • Market cap$2.2B as of 2026-08-21
  • 1-year return+64.5% 2025-08-21 close $16.15 → 2026-08-21 close $26.57
  • P/E12.18 as of 2026-08-24
  • Net margin+9.0% as of 2026-08-24
  • ROE+19.9% as of 2026-08-24
  • Debt / equity0.66 as of 2026-08-24
  • Revenue growth (YoY)+0.5% as of 2026-08-24
  • Beta0.60 as of 2026-08-24
  • Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)

Ask why MD looks like this →

How MD compares in its sector

  • price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
  • net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
  • operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
  • return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24

Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.

Ask how MD stacks up against peers →

Top 10 scores & list membership

MD is not currently in any published Top 10 list. Its scores are below.

Long-term score

Not scored for the long-term list: no shareholder return data.

Short-term score

56.5 #391 of 1,704 scored · #75 of 240 in Health Care

  • Trend52.4
  • Momentum44.3
  • Setup71.8
  • Volume and participation80.8
  • Catalysts40.3

Volume and participation 81st: it gapped 5.2% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; setup 72nd: day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move; weakest is catalysts 40th: the analyst consensus rating has softened toward "sell" since the prior reading.

Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.

How PEDIATRIX MEDICAL GROUP INC looks technically

PEDIATRIX MEDICAL GROUP INC (MD) is trading 17.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 244 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 11 trading days ago. It is 4.9% below its 52-week high (its highest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move.

Trend

8
Distance from the 200-dayit is trading 17.0% above its 200-day average, the long-term trend line — a longer-term uptrend+17.0%
50-day moving averageits average price over the last 50 trading days — a short-term trend line — is $25.73$25.73
200-day moving averageits average price over the last 200 trading days — the long-term trend line — is $22.72$22.72
Swing structureeach recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes nextlower highs and lower lows
Last swing turnits last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on14 sessions
Wave structureits recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 27.329. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C.possible downward five-wave sequence, in wave 3 (one of several readings)
Since the 50/200 crossits 50-day average crossed above its 200-day average about 244 trading days ago — a "golden cross", a bullish long-term signal244 sessions
Trend strength (14-day ADX)a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend)21.3

Momentum

3
14-day RSImomentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30)54.2
Position in its 14-day rangeit is trading near the top of its 14-day range ($22.60 to $27.33) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions.84.0
Since the MACD crossed zeroMACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish)29 sessions

Range

12
52-week highits highest closing price over the past year (about 252 trading days) was $27.94$27.94
From the 52-week highit is 4.9% below its 52-week high (its highest price of the past year)-4.9%
Above the 52-week lowit is 69.2% above its 52-week low (its lowest price of the past year)+69.2%
Below the 52-week highit is 4.9% below its highest point of the past year4.9%
Since a 20-day breakoutit made a new 20-day high about 11 trading days ago11 sessions
Since a 55-day breakoutit made a new 55-day high about 35 trading days ago35 sessions
All-time highits highest closing price on record is $86.09 (set on 2015-08-18)$86.09
Given back of the 52-week moveover the past year its closes ranged ($15.80 to $27.39), and it has given back only a small part of its rise from last year’s low — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.86 to $20.23. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast.7.1%
From the all-time highit is 69.1% below its all-time high-69.1%
Nearest price levelit is trading 6.5% above a support level at $24.86 — a price it turned at twice since 2025-11-28, most recently on 2026-06-15. Since 2024-08-21 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go.-6.5%
All-time lowits lowest closing price on record is $6.62 (set on 2024-07-09)$6.62
Above the all-time lowit is 301.4% above its all-time low+301.4%

Volatility

5
Band width vs its own 6 monthsday-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move5th percentile
Typical daily rangein a typical session it travels about $0.98 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was$0.98
Bollinger bands (20-day, ±2σ)most of its recent trading has stayed between about $25.43 and $27.26 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles$25.43 – $26.34 – $27.26
Typical daily range (% of price)its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price3.7%
Stretch from the 200-day averageit is trading 3.9 daily ranges above its 200-day average price (17.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale3.9 daily ranges above its 200-day average

Volume

1
Volume vs its 30-day averagetrading volume is about normal versus its 30-day average1.24×

Analyst

2
Change in the average price targetanalysts have raised their average price target by 0.6% since the prior reading+0.6%
Change in the consensus ratingthe analyst consensus rating has softened toward "sell" since the prior reading0.29 toward sell

Candlestick patterns

2
Since a doji2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level2 sessions ago
Since a bullish engulfingtoday it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before ittoday

Price gaps

3
Gap at the openit opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap-0.1%
Open gapit gapped 5.2% above the previous close 49 sessions ago and has not traded back through the level it left behind at 22.47 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed+5.2%
Gap filleda 10.3% gap down opened on 2026-08-04 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it13 sessions ago

Price streaks

1
Closing streakit closed higher in its latest session, after a session that did not close higher — a single up day rather than a run1 session up

Relative strength

4
vs market, 1 monthover the past 1 month this stock lagged the market by 0.7 percentage points (the stock gained 1.6% while the market gained 2.3%)-0.7%
vs market, 3 monthsover the past 3 months this stock beat the market by 20.2 percentage points (the stock gained 23.3% while the market gained 3.1%)+20.2%
vs market, 6 monthsover the past 6 months this stock beat the market by 30.1 percentage points (the stock gained 41.2% while the market gained 11.1%)+30.1%
vs market, 12 monthsover the past 12 months this stock beat the market by 44.0 percentage points (the stock gained 64.5% while the market gained 20.5%)+44.0%

Signal agreement

2
Bullish technical signals4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast4 of 9
Bearish technical signals2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast2 of 9

Trend (Ichimoku cloud)

1
Vs the Ichimoku cloudtrading 4.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.5% of the share price.+4.1%

Volume-weighted price

2
Vs this year’s average price paidthe price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $22.79 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP.+16.6%
Vs the average paid since it last reportedthe price is 1% above the average price paid since it last reported on 2026-07-15 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $26.19 — a volume-weighted average of daily closes over 28 sessions, not a true tick-by-tick VWAP.+1.5%

Price levels it has turned at before

MD last closed at $26.57 on 2026-08-21. Since 2024-08-21 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.

LevelSideDistanceEvidence
$24.86Support6.5% below the last closeturned there twice · 2025-11-28 to 2026-06-15
$23.77Support10.5% below the last closeturned there twice · 2026-04-28 to 2026-07-15
$22.85Support14.0% below the last closeturned there four times · 2025-12-16 to 2026-08-04

A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.

Wave structure

Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.

This labelling fails — stops being a possible reading at all — if it closes above $27.33.

This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.

On past moves of this shape the leg has usually ended somewhere between $18.69 and $21.99 — that is where it has tended to end if the count holds, not a forecast of where the price goes.

Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $27.33.

This reading has stood for 6 trading days, since 2026-08-14.

Read from daily closes as of 2026-08-21.

An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.

Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.

Ask about MD's technicals →

Analyst consensus

  • Consensus ratingHold (2.71 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
  • Mean price target$26.33 range $21.00 – $28.00; median $28.00

Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.

Analyst EPS estimate for MD

  • Consensus EPS estimate$0.6497 next reporting period, as of 2026-08-22

Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.

The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.

Ask how MD's estimates have moved →

Key risks (from latest filing)

["Significant reliance on government and third-party reimbursement programs for a majority of revenue.","Exposure to professional liability claims inherent in providing medical services.","Integration risks associated with acquiring and managing medical practices."]

See MD's biggest risks from its latest 10-Q →

What changed in the latest 10-Q

AI-assisted comparison of MD's 10-Q filed 2026-05-05 against the prior one filed 2025-11-03.

Management's Discussion & Analysis (MD&A)

  • Added:
    • Newer filing (2026-05-05) adds reference to '2025 Form 10-K' filed February 19, 2026, replacing older reference to '2024 Form 10-K' filed February 20, 2025
    • Newer filing adds 'or government-funded' to describe GHC Programs as 'government-sponsored or government-funded healthcare programs'
    • Newer filing adds text regarding IDR enforcement: 'though providers have had difficulty enforcing IDR awards against insurers'
    • Newer filing adds reference to 'the U.S. Department of Labor' as an enforcement agency for surprise billing violations
  • Removed:
    • Older filing (2025-11-03) contains entire 'Office-Based Practice Exits' section describing exits of office-based practices and primary/urgent care service line; this section is removed in newer filing
    • Older filing includes phrase 'or by states, one or both of which' regarding enforcement agencies; newer filing changes this to 'or by states, one or multiple of which'
  • Reworded:
    • Comparison period changed from 'three months ended September 30, 2025' in older filing to 'three months ended March 31, 2026' in newer filing
    • Comparison year changed from 'September 30, 2024' in older filing to 'March 31, 2025' in newer filing
    • Description of network services changed from 'We also provide services across multiple other pediatric subspecialties' in older filing to 'Our network also includes other pediatric subspecialists' in newer filing
    • Enforcement language changed from 'Centers for Medicare and Medicaid Services or by states' in older filing to 'Centers for Medicare and Medicaid Services, the U.S. Department of Labor, or by states' in newer filing
    • IDR outcome language expanded from 'may not affect an insurer's future offers of payment' in older filing to include 'though providers have had difficulty enforcing IDR awards against insurers' in newer filing
  • Notes:
    • Older filing text appears truncated at end of Healthcare Reform section; comparison limited to available text
    • Page number '13' appears in both filings but at different positions relative to content
    • All changes are factual differences between the two quarterly filings for different reporting periods

Risk Factors

The two filings could not be meaningfully compared for this section.

AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.

Ask what changed in MD's latest 10-Q →

Insider activity (SEC Form 4)

No open-market insider purchases or sales recorded in the last 90 days.

  • Last 180 days0 buys · 1 sell ($855665) — 1 selling insider

Most recent open-market transaction: 2026-05-13. As of 2026-08-24.

View full insider trading history → View SEC Form 3/4/5 filings

Ask about MD's insider activity →

Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.

Institutional ownership (13F)

5 institutional 13F filers reported holding MD as of 2026-03-31 (quarter-end position, filed within 45 days).

  • Distinct 13F filers 5
  • Reported shares held 20,825,607
  • Reported value $445,459,752

reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".

Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.

Ask about MD's institutional holders →

Short interest (FINRA)

MD had 4,139,091 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).

MD had 5.09% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.63 days to cover at the same settlement.

  • Reported short interest (shares) 4,139,091
  • Short interest (% of shares outstanding) 5.09%
  • Prior settlement (shares) 4,908,297
  • Reported change -15.67%
  • Days to cover (reported) 6.63

Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.

Ask about MD's short interest →

Competitors & peers

  • Envision Healthcare
  • TeamHealth
  • MEDNAX Services (Internal/Legacy)

AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.

Not quite? Describe exactly what you want →

PEDIATRIX MEDICAL GROUP INC is found in…

Frequently asked questions

What does PEDIATRIX MEDICAL GROUP INC (MD) do?

Pediatrix Medical Group is a national medical group that provides physician and other clinical services in neonatal, maternal-fetal, pediatric, and other pediatric subspecialties. The company operates through a network of affiliated physician practices, delivering integrated care to infants, children, and their families across various clinical settings.

What sector is PEDIATRIX MEDICAL GROUP INC (MD) in?

PEDIATRIX MEDICAL GROUP INC (MD) is classified in the Health Care sector. Its industry is Healthcare Services - Physician Groups. It trades on NYSE.

Who are PEDIATRIX MEDICAL GROUP INC's (MD) competitors?

Notable peers of PEDIATRIX MEDICAL GROUP INC (MD) include Envision Healthcare, TeamHealth and MEDNAX Services (Internal/Legacy). This peer set is informational only — not financial advice.

Is PEDIATRIX MEDICAL GROUP INC (MD) overbought or oversold right now?

PEDIATRIX MEDICAL GROUP INC (MD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.

Where does stocks-llm's data on MD come from?

Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-08-21.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.

Research stocks in your own words.

Informational only — NOT financial advice.

ScreenersBlogPrivacyiOS app